News
ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And DoneTM ...
Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial ...
ANI Pharmaceuticals' Q2 2025 earnings report highlights record revenues, strong Cortrophin Gel demand, and raised guidance.
Meditherapy Retinal Skin Booster Serum Meditherapy's Retinal Skin Booster Serum Hits #1 on Amazon Prime Day, Loved for Its Gentle, Multi-Ta ...
People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...
3d
TipRanks on MSNAdverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28)
We are thrilled to report excellent progress in the ARTEMIS Phase 3 trial, with enrollment driven by robust interest from retina specialists and ...
Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.
A petition to get Larochelle a Victoria Cross has been submitted to the House of Commons by Nipissing-Timiskaming MP Pauline ...
SHOPPING: Every small business needs tech - whether it's work phones, laptops, monitors or headphones - in the digital world, ...
GAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024. Net loss (GAAP) ...
Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results